Connection

Yusuf Hannun to Genetic Vectors

This is a "connection" page, showing publications Yusuf Hannun has written about Genetic Vectors.
Connection Strength

0.208
  1. Combined therapeutic use of AdGFPFasL and small molecule inhibitors of ceramide metabolism in prostate and head and neck cancers: a status report. Cancer Gene Ther. 2006 Dec; 13(12):1045-51.
    View in: PubMed
    Score: 0.060
  2. Biochemical properties of mammalian neutral sphingomyelinase 2 and its role in sphingolipid metabolism. J Biol Chem. 2003 Apr 18; 278(16):13775-83.
    View in: PubMed
    Score: 0.048
  3. Safety study of adeno-associated virus serotype 2-mediated human acid sphingomyelinase expression in the nonhuman primate brain. Hum Gene Ther. 2012 Aug; 23(8):891-902.
    View in: PubMed
    Score: 0.023
  4. Stress-induced sphingolipid signaling: role of type-2 neutral sphingomyelinase in murine cell apoptosis and proliferation. PLoS One. 2010 Mar 23; 5(3):e9826.
    View in: PubMed
    Score: 0.020
  5. Acid ceramidase inhibition: a novel target for cancer therapy. Front Biosci. 2008 Jan 01; 13:2293-8.
    View in: PubMed
    Score: 0.017
  6. Neutral ceramidase encoded by the Asah2 gene is essential for the intestinal degradation of sphingolipids. J Biol Chem. 2006 Mar 17; 281(11):7324-31.
    View in: PubMed
    Score: 0.015
  7. Sphingosine kinase 1 (SPHK1) is induced by transforming growth factor-beta and mediates TIMP-1 up-regulation. J Biol Chem. 2004 Dec 24; 279(52):53994-4001.
    View in: PubMed
    Score: 0.013
  8. Quantification and characterization of the bystander effect in prostate cancer cells following adenovirus-mediated FasL expression. Cancer Gene Ther. 2003 Apr; 10(4):330-9.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.